ARMP • AMEX
Armata Pharmaceuticals, Inc.
$11.86
Stock Details
| Market Cap | 431,785,834 |
|---|---|
| Day Change | 2.32 (24.32%) |
| Volume | 149,465 |
| Avg Volume | 47,786 |
| Price Range | 0.9-16.34 |
Overview
| Country | US |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | AMEX |
Company Profile
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Financial Overview
| 52 Week High | 16.34 |
|---|---|
| 52 Week High Date | 2025-10-22 |
| 52 Week Low | 0.8981 |
| 52 Week Low Date | 2025-04-09 |
| 10D Avg Trading Vol | 0.03774 |
| YTD Price Return Daily | 39.0127 |
| MTD Price Return Daily | 30.2985 |
Cash Flow
| TTM/Share | -1.62294 |
|---|---|
| Annual/Share | -1.0897 |
| Quarterly/Share | -0.8867 |
Price-to-Earnings
| Annual Ratio | 0.2344 |
|---|---|
| Quarterly Ratio | 0.0626 |
| TTM |
Revenue
| 3Y Growth | 5 |
|---|---|
| 5Y Growth | |
| Annual/Share | |
| TTM/Share | 0.1898 |
| 5Y Share Growth |
Earnings Per Share
| Annual | -0.5231 |
|---|---|
| 3Y Growth | |
| 5Y Growth | |
| Quarterly YOY Growth |
Price-to-Book
| Ratio | 18.1844 |
|---|---|
| Annual Ratio | 1.2422 |
| TTM | 2.1573 |